Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Published: 2024-03-15 (Crawled : 13:00) - globenewswire.com
ONCT | News | $8.79 -1.79% -1.82% 2.8K
|
Health Technology
|
| O: -4.32%
H: 8.26%
C: 7.19%
cancer treatment key
Water Treatment Equipment Market size in Power Industry to grow by USD 1.34 billion from 2022 to 2027, Increasing power demand to drive the growth, Technavio
Published: 2024-03-15 (Crawled : 08:00) - prnewswire.com
XYL | $127.16 0.75% 0.0% 1.1M
|
Producer Manufacturing
|
| O: -0.91%
H: 1.14%
C: 0.37%
ECL | $219.21 -0.02% 0.0% 920K
|
Process Industries
|
| O: -0.98%
H: 2.03%
C: 1.83%
water treatment market
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $222.18 -2.7% -2.8% 270K
|
Health Technology
|
| O: 20.66%
H: 2.07%
C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
MIRM | $23.6 -1.05% -1.06% 400K
|
Health Technology
|
| O: 1.49%
H: 2.98%
C: -0.43%
fda pruritus approval treatment livmarli
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
PSTX | News | $2.005 -1.72% -1.75% 520K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -4.14%
fda drug granted treatment designation therapeutics
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
Published: 2024-03-13 (Crawled : 13:00) - globenewswire.com
FEMY | News | $1.305 0.39% 0.38% 190K
|
Manufacturing
|
| O: -5.76%
H: 12.78%
C: 0.56%
treatment
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Published: 2024-03-13 (Crawled : 12:00) - prnewswire.com
NRBO | $3.425 -1.01% -1.02% 23K
|
Health Technology
|
| O: 3.49%
H: 0.2%
C: -11.31%
da-1241 approval review treatment pharmaceuticals trial
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
CPRX | $15.35 -4.06% -4.23% 1.4M
|
Health Technology
|
| O: 1.46%
H: 3.13%
C: 1.12%
agamree treatment pharmaceuticals duchenne
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Published: 2024-03-13 (Crawled : 11:00) - prnewswire.com
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: 0.69%
H: 1.1%
C: -0.71%
ion224 positive treatment results study
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PCRX | $26.12 -2.43% -2.49% 620K
|
Health Technology
|
| O: 0.03%
H: 1.24%
C: -0.92%
pcrx-201 osteoarthritis granted treatment designation therapy
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PEPG | $11.9 3.48% 3.36% 47K
|
|
| O: 1.94%
H: 4.94%
C: -2.9%
edo51 fda rare drug disease treatment duchenne
Global Immune Thrombocytopenia Drug Markets, 2019-2022 and 2023-2029: Advanced Drug Delivery Technologies Transform Management, Second-Generation TPO-RAs Revolutionize Treatment Options
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
drug treatment global advanced
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
CRNX | $43.005 -2.28% -2.34% 540K
|
Health Technology
|
| O: 0.81%
H: 2.03%
C: -1.41%
positive treatment topline trial results
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Published: 2024-03-12 (Crawled : 20:00) - prnewswire.com
PGEN | $1.33 1.53% 1.5% 1.1M
|
Health Technology
|
| O: 0.33%
H: 3.97%
C: 0.66%
prgn-2012 respiratory treatment immunotherapy
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
Published: 2024-03-12 (Crawled : 13:00) - globenewswire.com
MGRX | $0.291 3.19% 3.09% 270K
|
|
| O: -2.97%
H: 18.53%
C: 5.15%
kyzatrex fda approved treatment therapy
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.22 -5.13% -5.41% 200K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
LXRX | News | $1.625 0.31% 0.31% 3.7M
|
Health Technology
|
| O: 0.36%
H: 0.32%
C: -10.64%
disease kidney control treatment diabetes study
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PLRX | $12.23 -4.9% -5.15% 360K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
treatment fibrosis bexotegrast therapeutics
Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million, 42% of market growth is expected in North America, Technavio
Published: 2024-03-12 (Crawled : 04:00) - prnewswire.com
ELDN | $1.99 26.75% 21.11% 310K
|
Manufacturing
|
| O: 1.73%
H: 1.7%
C: -7.39%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.6%
H: 0.74%
C: -3.66%
BCLI | $0.503 -6.99% -7.51% 1.1M
|
Health Technology
|
| O: -2.43%
H: 2.8%
C: -4.02%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.86%
expected sclerosis treatment growth market
Hyperpigmentation Treatment Market to Reach $10.5 Billion, Globally, by 2032 at 7.5% CAGR: Allied Market Research
Published: 2024-03-11 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
reach treatment research market
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.